Julius A. Vida

Total Page:16

File Type:pdf, Size:1020Kb

Julius A. Vida MEDICINAL CHEMISTRY A Series of Monographs EDITED BY GEORGE DESTEVENS Pharmaceuticals Division, CIBA-GEIGY Corporation Summit, New Jersey Volume 1. GEORGE DESTEVENS. Diuretics: Chemistry and Pharmacology. 1963 Volume 2. RODOLFO PAOLETTI (ED.). Lipid Pharmacology. Volume I. 1964. RODOLFO PAOLETTI AND CHARLES J. GLUECK (EDS.). Volume II. 1976 Volume 3. E. J. ARIENS (ED.) . Molecular Pharmacology: The Mode of Action of Biologically Active Compounds. (In two volumes.) 1964 Volume 4. MAXWELL GORDON (ED.). Psychopharmacological Agents. Volume 1.1964. Volume II. 1967. Volume III. 1974. Volume IV. 1976 Volume 5. GEORGE DESTEVENS (ED.). Analgetics. 1965 Volume 6. ROLAND H. THORP AND LEONARD B. COBBIN. Cardiac Stimulant Substances. 1967 Volume 7. EMIL SCHLITTLER (ED.). Antihypertensive Agents. 1967 Volume 8. U. S. VON EULER AND RUNE ELIASSON. Prostaglandins. 1967 Volume 9. G. D. CAMPBELL (ED.). Oral Hypoglycaemic Agents: Pharma- cology and Therapeutics. 1969 Volume 10. LEMONT B. KIER. Molecular Orbital Theory in Drug Research. 1971 Volume 11. E. J. ARIENS (ED.). Drug Design. Volumes I and II. 1971. Vol- ume III. 1972. Volume IV. 1973. Volumes V and VI. 1975. Volume VII. 1976 Volume 12. PAUL E. THOMPSON AND LESLIE M. WERBEL. Antimalarial Agents: Chemistry and Pharmacology. 1972 Volume 13. ROBERT A. SCHERRER AND MICHAEL W. WHITEHOUSE (Eds.). Antiinflammatory Agents: Chemistry and Pharmacology. (In two vol- umes.) 1974 Volume 14. LEMONT B. KIER AND LOWELL H. HALL. Molecular Connectiv- ity in Chemistry and Drug Research. 1976 Volume 15. JULIUS A. VIDA. Anticonvulsants. 1977 ANTICONVULSANTS Edited by Julius A. Vida Bristol Myers Company International Division New York, New York ACADEMIC PRESS New York San Francisco London 1977 A Subsidiary of Harcourt Brace Jovanovich, Publishers COPYRIGHT © 1977, BY ACADEMIC PRESS, INC. ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER. ACADEMIC PRESS, INC. Ill Fifth Avenue, New York, New York 10003 United Kingdom Edition published by ACADEMIC PRESS, INC. (LONDON) LTD. 24/28 Oval Road, London NW1 Library of Congress Cataloging in Publication Data Main entry under title: Anticonvulsants. (Medicinal chemistry series ; no. ) Includes bibliographies and index. 1. Epilepsy—Chemotherapy. 2. Anticonvulsants— Therapeutic use. 3. Anticonvulsants-Testing. 4. Neuropharmacology. I. Vida, Julius A., Date II. Series: Medicinal chemistry, a series of monographs ; no. RC374.C48A57 616.8'53'θ61 76-19492 ISBN 0-12-721840-8 PRINTED IN THE UNITED STATES OF AMERICA TO MY WIFE, MARTHA LIST OF CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors' contributions begin. JOHN D. ALVIN (113), School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania MILTON T. BUSH (113), Vanderbilt Medical School, Nashville, Tennessee BRIAN B. GALLAGHER (11), Departments of Pharmacology and Neurology, Schools of Medicine and Dentistry, Georgetown University, Washington, D.C. ELISABETH H. GERRY (151), Kendall Company, Lexington, Massachusetts LEMONT B. KIER (577), Department of Chemistry, Massachusetts College of Pharmacy, Boston, Massachusetts WALLACE J. MURRAY (577), Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska NICHOLAS P. PLOTNIKOFF (293), Abbott Laboratories, North Chicago, Illinois FRANK D. POPP* (329), Department of Chemistry, Clarkson College of Technology, Potsdam, New York JOHN F. REINHARD (57), Department of Pharmacology, Massachusetts College of Phar- macy, Boston, Massachusetts JOHN F. REINHARD, JR. (57), Laboratory of Neuroendocrine^Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Mas- sachusetts JULIUS A. VIDA (1, 151), Bristol Myers Company, International Division, New York, New York HAROLD E. ZAUGG (293), Abbott Laboratories, North Chicago, Illinois *Present address: Department of Chemistry, University of Missouri, Kansas City, Missouri. xi PREFACE From 1960 to 1974 no new anticonvulsant drug was marketed in the United States (with the exception of diazepam, which was marketed primarily as a minor tranquilizer). With the approval in 1974 of car- bamazepine, the marketing in 1975 of clonazepam, and the anticipated marketing in 1977/1978 of sodium dipropylacetate, eterobarb, mexiletine, and possibly others, a resurgence of interest in anticonvulsant drugs is apparent in the United States. Interest in anticonvulsant drugs never ceased outside the United States as witnessed by the introduction of many new drugs to the international market since 1961. Many years have passed since the publication of the excellent chapter, Anticonvulsant Drugs, by W. J. Close and M. A. Spielman in "Medicinal Chemistry" (W. H. Härtung, ed., Wiley, New York, 1961). Although many other interesting books have appeared on the subject (e.g., "Basic Mechanisms of the Epilepsies," H. H. Jasper, A. A. Ward, and A. Pope, eds., Little, Brown, Boston, Massachusetts, 1969; "Anticonvulsant Drugs," D. M. Woodbury, J. K. Penry, and R. P. Schmidt, eds., Raven, New York, 1972; "Anticonvulsant Drugs, International Encyclopedia of Pharmacology and Therapeutics," J. Mercier, ed., Pergamon, Oxford, 2 volumes, 1973), none was intended specifically for the medicinal chemist. In the late 1960's and early 1970's the need for a new book became apparent to many of us working jointly for the Kendall Company in Cambridge, Massachusetts. Drs. John F. Reinhard, Milton T. Bush, Brian B. Gallagher, and myself, among others, were involved, respec- tively, in the laboratory evaluation, drug disposition, clinical evaluation, and synthesis and design of anticonvulsant drugs. Although hundreds of compounds have been synthesized since 1959, no systematic treatise on anticonvulsant drugs has been written since the chapter by Close and Spielman. I proposed writing this book to the aforementioned researchers and, later, to others. The idea appealed to all, for which I am grateful. Xlll Preface χιν Although this work was written specifically for the medicinal chemist, biochemists, neurologists, and pharmacologists should also find it of interest. Chapter 1 provides an overview and Chapter 2 a neurophar- macological background. Chapter 3 details the laboratory evaluation of compounds and Chapter 4 deals with drug disposition. Chapters 5 through 8 describe the chemistry and biological activities of the various classes of anticonvulsant compounds. Specifically, Chapter 5 contains the cyclic ureides, Chapter 6 the benzopyrans, Chapter 7 other heterocyclic drugs, and Chapter 8 the noncyclic anticonvulsants. Since compilation of data depends on availability in the literature, it was not possible to treat each topic uniformly. Since the chapter by Close and Spielman covered the literature through 1958, ours begins with 1959 and extends to 1976. I am grateful to the following people for their help: Mrs. Mary-Lou O'Shea (formerly with Kendall Co., presently with NIAMDD) and Dr. William R. Wilber (formerly with Kendall Co., presently with Rohm and Haas Co.) for literature searches; Mrs. Claire Gibbons and Miss Debbie Hudson (Kendall Co.), Mrs. Sandra Meech and Mrs. Sharon Yaddow (Bristol Laboratories), and the secretaries of the contributors for typing parts of the manuscript; Dr. J. Kiffin Penry and Mr. Lawrence D. Smith (National Institutes of Neurological and Communicative Disorders and Stroke, National Institute of Health) for providing data and literature printouts; Dr. Paul Szentmiklosi and Mrs. Alexandra Andor (Medimpex, Budapest) for providing data on decimemide; Mr. Louis Chauvet (Or- symonde S.A., Paris) for providing data on doxenitoin; my former classmate, Mrs. Martha Windholz (Merck, Sharp & Dohme Research Laboratories), for providing literature data; Mrs. Suzanne Woodbury (Georgetown University) for providing data and illustrations; Dr. Jonas A. Gylys (Bristol Laboratories) for reading part of the manuscript; Dr. George deStevens (Ciba-Geigy Corporation) and Dr. Warren J. Close (Abbott Laboratories) for their encouragement; and particularly Dr. Maxwell Gordon (Bristol Laboratories) for his help and encouragement. I wish to express my thanks to all of the contributors to the book. My special thanks are due Dr. Brian B. Gallagher for his constructive review of parts of the manuscript. Above all, my thanks are due my wife for her assistance and understanding during the genesis of this book. Julius A. Vida 1 ADVANCES IN ANTICONVULSANT DRUG DEVELOPMENT Julius A. Vida The first effective anticonvulsant drug, sodium bromide, was introduced by Charles Locock (1857). In the absence of other drugs, bromide therapy of epileptics became popular. The disadvantages of bromide therapy were discovered, however, quite early: The bromides have an unfavorable thera- peutic ratio. Prolonged treatment of epileptic patients with sodium bromide or other bromide preparations causes chronic toxicity manifested by seda- tion, psychic disturbances, skin rashes, increased glandular secretion, and gastric distress. The second and still one of the most important drugs for the treatment of epilepsy, phénobarbital, was introduced by Alfred Hauptmann (1912). Phénobarbital is generally considered to be the drug of choice for the treat- ment of generalized tonic-clonic seizures. It is also the drug of choice for the management of epileptic
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Genetically Modified Baculoviruses for Pest
    INSECT CONTROL BIOLOGICAL AND SYNTHETIC AGENTS This page intentionally left blank INSECT CONTROL BIOLOGICAL AND SYNTHETIC AGENTS EDITED BY LAWRENCE I. GILBERT SARJEET S. GILL Amsterdam • Boston • Heidelberg • London • New York • Oxford Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo Academic Press is an imprint of Elsevier Academic Press, 32 Jamestown Road, London, NW1 7BU, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA ª 2010 Elsevier B.V. All rights reserved The chapters first appeared in Comprehensive Molecular Insect Science, edited by Lawrence I. Gilbert, Kostas Iatrou, and Sarjeet S. Gill (Elsevier, B.V. 2005). All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publishers. Permissions may be sought directly from Elsevier’s Rights Department in Oxford, UK: phone (þ44) 1865 843830, fax (þ44) 1865 853333, e-mail [email protected]. Requests may also be completed on-line via the homepage (http://www.elsevier.com/locate/permissions). Library of Congress Cataloging-in-Publication Data Insect control : biological and synthetic agents / editors-in-chief: Lawrence I. Gilbert, Sarjeet S. Gill. – 1st ed. p. cm. Includes bibliographical references and index. ISBN 978-0-12-381449-4 (alk. paper) 1. Insect pests–Control. 2. Insecticides. I. Gilbert, Lawrence I. (Lawrence Irwin), 1929- II. Gill, Sarjeet S. SB931.I42 2010 632’.7–dc22 2010010547 A catalogue record for this book is available from the British Library ISBN 978-0-12-381449-4 Cover Images: (Top Left) Important pest insect targeted by neonicotinoid insecticides: Sweet-potato whitefly, Bemisia tabaci; (Top Right) Control (bottom) and tebufenozide intoxicated by ingestion (top) larvae of the white tussock moth, from Chapter 4; (Bottom) Mode of action of Cry1A toxins, from Addendum A7.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Pharmacovigilance & Clinical Trials
    Penichet KO, Clin Exp Pharmacol 2012, 2:3 http://dx.doi.org/10.4172/2161-1459.S1.005 International Conference and Exhibition on Pharmacovigilance & Clinical Trials October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA A comparison of the toxicity effects of the anticonvulsant eterobarb and phenobarbital in normal human volunteers Penichet KO New York Medical College, USA enewed corporate interest in the anticonvulsant drug eterobarb justified renewed clinical and experimental interest in this Rdrug. The unique and clinically intriguing feature of eterobarb is that while sharing the anticonvulsant properties of other barbiturates, the hypnotic side effects usually associated with barbiturates appear to be absent in animal studies and greatly reduced in clinical trials. This study was designed to compare the hypnotic effects of eterobarb with those of phenobarbital in healthy normal human volunteers using a double-blind, placebo-controlled design. Both clinical and neuropsychological parameters of toxicity were measured, while blood barbiturate levels were monitored to correlate neurobehavioral changes with total barbiturate level. As expected, there is a linear relationship between the degree of toxicity and the barbiturate level, but much higher barbiturate levels were tolerated without toxicity by subjects taking eterobarb. For ethical reasons, subjects were not maintained at high levels of toxicity over the 10-week trial. However, both eterobarb and phenobarbital recipients failed to show significant improved performance on Digits Total, a test of mental flexibility (Digit Symbol Substitution). In addition, phenobarbital recipients showed the only significant decrement of performance on Digits Total, and they failed to improve significantly on Trails-Part A, in which all other groups improved.
    [Show full text]
  • Discovery, Synthesis and Structure-Activity Relationship Study
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 12-18-2020 Antiparasitic Peptide from the Ocean: Discovery, Synthesis and Structure-Activity Relationship Study Kh Tanvir Ahmed Follow this and additional works at: https://dsc.duq.edu/etd Part of the Medicinal Chemistry and Pharmaceutics Commons Recommended Citation Ahmed, K. (2020). Antiparasitic Peptide from the Ocean: Discovery, Synthesis and Structure-Activity Relationship Study (Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1924 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. ANTIPARASITIC PEPTIDE FROM THE OCEAN: DISCOVERY, SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDY A Thesis Submitted to the Graduate School of Pharmaceutical Sciences Duquesne University In partial fulfillment of the requirements for the degree of Master of Science By Kh Tanvir Ahmed December 2020 Copyright by Kh Tanvir Ahmed 2020 ANTIPARASITIC PEPTIDE FROM THE OCEAN: DISCOVERY, SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDY By Kh Tanvir Ahmed Approved August 21, 2020 ________________________________ ________________________________ Kevin J. Tidgewell, Ph.D. Aleem Gangjee, Ph.D. Associate Professor of Medicinal Professor of Medicinal Chemistry Chemistry (Committee Member) (Committee Chair) ________________________________ ________________________________
    [Show full text]
  • Downloaded, Instead, and Converted to 3D Using Obabel (O’Boyle Et Al., 2011)
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.30.225821; this version posted July 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 New tyrosinases with a broad spectrum of action against contaminants of emerging 2 concern: Insights from in silico analyses 3 4 Marcus V. X. Senra† & Ana Lúcia Fonseca 5 6 Instituto de Recursos Naturais, Universidade Federal de Itajubá, 37500-903, Itajubá, Minas 7 Gerais – Brazil 8 †Corresponding author – [email protected]; Orcid - 0000-0002-3866-8837 9 10 Abstract 11 Tyrosinases (EC 1.14.18.1) are type-3 copper metalloenzymes with strong oxidative capacities 12 and low allosteric selectivity to phenolic and non-phenolic aromatic compounds that have been 13 used as biosensors and biocatalysts to mitigate the impacts of environmental contaminants over 14 aquatic ecosystems. However, the widespread use of these polyphenol oxidases is limited by 15 elevated production costs and restricted knowledge on their spectrum of action. Here, six 16 tyrosinase homologs were identified and characterized from the genomes of 4 widespread 17 freshwater ciliates using bioinformatics. Binding energies between 3D models of these 18 homologs and ~1000 contaminants of emerging concern (CECs), including fine chemicals, 19 pharmaceuticals, personal care products, illicit drugs, natural toxins, and pesticides were 20 estimated through virtual screening, suggesting their spectrum of action and potential uses in 21 environmental biotechnology might be considerably broader than previously thought.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al
    US00779531 OB2 (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee et al. (45) Date of Patent: Sep. 14, 2010 (54) METHODS AND REAGENTS FOR THE WO WO 2005/025673 3, 2005 TREATMENT OF METABOLIC DISORDERS OTHER PUBLICATIONS (75) Inventors: Margaret S. Lee, Middleton, MA (US); Tenenbaum et al., “Peroxisome Proliferator-Activated Receptor Grant R. Zimmermann, Somerville, Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in MA (US); Alyce L. Finelli, Patients With Coronary Artery Disease'. Circulation, 2004, pp. 2197 Framingham, MA (US); Daniel Grau, 22O2.* Shen et al., “Effect of gemfibrozil treatment in sulfonylurea-treated Cambridge, MA (US); Curtis Keith, patients with noninsulin-dependent diabetes mellitus'. The Journal Boston, MA (US); M. James Nichols, of Clinical Endocrinology & Metabolism, vol. 73, pp. 503-510, Boston, MA (US) 1991 (see enclosed abstract).* International Search Report from PCT/US2005/023030, mailed Dec. (73) Assignee: CombinatoRx, Inc., Cambridge, MA 1, 2005. (US) Lin et al., “Effect of Experimental Diabetes on Elimination Kinetics of Diflunisal in Rats.” Drug Metab. Dispos. 17:147-152 (1989). (*) Notice: Subject to any disclaimer, the term of this Abstract only. patent is extended or adjusted under 35 Neogi et al., “Synthesis and Structure-Activity Relationship Studies U.S.C. 154(b) by 0 days. of Cinnamic Acid-Based Novel Thiazolidinedione Antihyperglycemic Agents.” Bioorg. Med. Chem. 11:4059-4067 (21) Appl. No.: 11/171,566 (2003). Vessby et al., “Effects of Bezafibrate on the Serum Lipoprotein Lipid and Apollipoprotein Composition, Lipoprotein Triglyceride Removal (22) Filed: Jun. 30, 2005 Capacity and the Fatty Acid Composition of the Plasma Lipid Esters.” Atherosclerosis 37:257-269 (1980).
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]